Skip to content

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double

71
Expert
Chimera Difficulty Score
a synthesis of Flesch-Kincaid, Coleman-Liau, SMOG, and Dale-Chall readability metrics
Abstract Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases. The SYNCHRONIZE-MASLD phase 3, randomized, double-blind, placebo-controlled trial included 216 adults (131 female and 85 male) with obesity (defined as a body mass index ≥30 kg m−2 or ≥27 kg m−2 with at least one obesity complication) and at-risk ...
**ACADEMIC MODE** **Methodology Check:** The SYNCHRONIZE-MASLD trial employed a rigorous randomized, double-blind, placebo-controlled design with clear co-primary endpoints. The sample size (n=216) was adequate for detecting clinically meaningful differences, and the use of MRI-PDFF for LFC assessment is a validated noninvasive measure. However, the 48-week duration limits long-term efficacy and safety insights, and the exclusion of participants with advanced fibrosis may restrict generalizabili...